[Federal Register Volume 69, Number 189 (Thursday, September 30, 2004)]
[Notices]
[Pages 58539-58540]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-21947]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to 21 CFR 1301.33(a), this is notice that on July 7, 2004, 
Cambridge Isotope Laboratory, 50 Frontage Road, Andover, Massachusetts 
01810, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of

[[Page 58540]]

the basic classes of controlled substances listed:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Methaqualone (2565)........................  I
Dimethyltryptamine (7435)..................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzzoylecgonine (9180)....................  II
Methadone (9250)...........................  II
Dextropropoxyphene (9273)..................  II
Morphine (9300)............................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances to produce isotope labeled standards for drug 
analysis.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: DEA Federal Register Representative 
(CCD) and must be filed no later than November 29, 2004.

    Dated: September 16, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-21947 Filed 9-29-04; 8:45 am]
BILLING CODE 4410-09-M